```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, is a a valuable scientific reagent extensively used in cardiovascular investigations. This Fab fragment selectively targets the glycoprotein IIb/IIIa receptor on thrombocytes , preventing clot formation . Consequently , it's commonly applied as a tool to explore the pathways underlying clotting and to assess the efficacy of antiplatelet medications . Availability is typically restricted to academic settings.
```
Abciximab Drug Research: Utilizing C7E3 Antibody and Compound 143653-53-6 in Scientific Assessments
Ongoing research into abciximab, a GPIIb/IIIa, frequently utilizes the Abciximab antibody monoclonal antibody C7E3 and the chemical compound identified as 143653-53-6. These materials are crucial for examining abciximab's mechanism of action, evaluating its effectiveness in different patient populations, and exploring potential indicators of therapeutic success. Additional exploration leveraging these precise reagents is expected to yield valuable information for optimizing therapeutic strategies involving cardiovascular conditions.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Investigating Research Opportunities with this Glycoprotein IIb/IIIa Inhibitor 143653-53-6 and C7E3
Recent studies suggest that Abciximab (identified as 143653-53-6) presents significant research potential, particularly when associated with C7E3. Initial observations suggested that this combination might improve clinical results in multiple cardiovascular settings. Further exploration is directed on defining the precise mode of action between this inhibitor and C7E3, encompassing analysis of platelet cohesion and vascular preservation.
- Future study endeavors seek to maximize administration approaches.
- Laboratory models are are being utilized to further assess the propositions.
- Human assessments will be necessary to thoroughly assess clinical efficacy.
```
Abciximab (C7E3) for Research: Specifications and Characteristics (143653-53-6)
Researchers requiring abciximab for experimental research should rigorously evaluate integrity and precise parameters . Material 143653-53-6 is typically supplied as a solid powder and comprehensive analytical documentation including assessment by mass spectrometry , binding affinity assays, and endotoxin level testing must be available. Verify the source’s certificate of analysis outlines acceptable ranges for related substances and fulfills all quality assurance standards .
High-Purity C7E3 Details & Supply
Acquiring analytical-grade Abciximab, specifically referencing the molecule C7E3 and identified by the product number 143653-53-6, requires detailed consideration of its origin . This antibody is widely utilized in cell-based investigations , particularly those involving platelet adhesion and thrombosis . Existing suppliers offer this reagent in varying amounts , typically ranging from g to larger commercial amounts . Kindly suggest reviewing the report of quality to verify purity and applicability for your specific application . Furthermore , confirm the expiration date before obtaining to maintain maximum effectiveness.
- Common Purity: >95%
- Storage Conditions: -20°C or suitable conditions
- Intended Purpose: Platelet Clumping Blocking Studies